227 related articles for article (PubMed ID: 12604689)
1. Selective tryptic cleavage at the tethered ligand site of the amino terminal domain of proteinase-activated receptor-2 in intact cells.
Al-Ani B; Hollenberg MD
J Pharmacol Exp Ther; 2003 Mar; 304(3):1120-8. PubMed ID: 12604689
[TBL] [Abstract][Full Text] [Related]
2. Proteinase-activated receptor-2: key role of amino-terminal dipeptide residues of the tethered ligand for receptor activation.
Al-Ani B; Hansen KK; Hollenberg MD
Mol Pharmacol; 2004 Jan; 65(1):149-56. PubMed ID: 14722246
[TBL] [Abstract][Full Text] [Related]
3. Protease-activated receptor-1 can mediate responses to SFLLRN in thrombin-desensitized cells: evidence for a novel mechanism for preventing or terminating signaling by PAR1's tethered ligand.
Hammes SR; Coughlin SR
Biochemistry; 1999 Feb; 38(8):2486-93. PubMed ID: 10029543
[TBL] [Abstract][Full Text] [Related]
4. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy.
Kuliopulos A; Covic L; Seeley SK; Sheridan PJ; Helin J; Costello CE
Biochemistry; 1999 Apr; 38(14):4572-85. PubMed ID: 10194379
[TBL] [Abstract][Full Text] [Related]
5. Extrapancreatic trypsin-2 cleaves proteinase-activated receptor-2.
Alm AK; Gagnemo-Persson R; Sorsa T; Sundelin J
Biochem Biophys Res Commun; 2000 Aug; 275(1):77-83. PubMed ID: 10944445
[TBL] [Abstract][Full Text] [Related]
6. Protease-activated receptor-2 (PAR-2): structure-function study of receptor activation by diverse peptides related to tethered-ligand epitopes.
Maryanoff BE; Santulli RJ; McComsey DF; Hoekstra WJ; Hoey K; Smith CE; Addo M; Darrow AL; Andrade-Gordon P
Arch Biochem Biophys; 2001 Feb; 386(2):195-204. PubMed ID: 11368342
[TBL] [Abstract][Full Text] [Related]
7. Proteinase-activated receptor 2 (PAR(2)): development of a ligand-binding assay correlating with activation of PAR(2) by PAR(1)- and PAR(2)-derived peptide ligands.
Al-Ani B; Saifeddine M; Kawabata A; Renaux B; Mokashi S; Hollenberg MD
J Pharmacol Exp Ther; 1999 Aug; 290(2):753-60. PubMed ID: 10411588
[TBL] [Abstract][Full Text] [Related]
8. Proteinase-activated receptor-2 in rat aorta: structural requirements for agonist activity of receptor-activating peptides.
Hollenberg MD; Saifeddine M; al-Ani B
Mol Pharmacol; 1996 Feb; 49(2):229-33. PubMed ID: 8632754
[TBL] [Abstract][Full Text] [Related]
9. Modified proteinase-activated receptor-1 and -2 derived peptides inhibit proteinase-activated receptor-2 activation by trypsin.
Al-Ani B; Saifeddine M; Wijesuriya SJ; Hollenberg MD
J Pharmacol Exp Ther; 2002 Feb; 300(2):702-8. PubMed ID: 11805236
[TBL] [Abstract][Full Text] [Related]
10. Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides.
Hollenberg MD; Saifeddine M; al-Ani B; Kawabata A
Can J Physiol Pharmacol; 1997 Jul; 75(7):832-41. PubMed ID: 9315351
[TBL] [Abstract][Full Text] [Related]
11. Glycosylation of human proteinase-activated receptor-2 (hPAR2): role in cell surface expression and signalling.
Compton SJ; Sandhu S; Wijesuriya SJ; Hollenberg MD
Biochem J; 2002 Dec; 368(Pt 2):495-505. PubMed ID: 12171601
[TBL] [Abstract][Full Text] [Related]
12. Endothelium-dependent and -independent responses to protease-activated receptor-2 (PAR-2) activation in mouse isolated renal arteries.
Moffatt JD; Cocks TM
Br J Pharmacol; 1998 Oct; 125(4):591-4. PubMed ID: 9831889
[TBL] [Abstract][Full Text] [Related]
13. Hepta and octapeptide agonists of protease-activated receptor 2.
Devlin MG; Pfeiffer B; Flanagan B; Beyer RL; Cocks TM; Fairlie DP
J Pept Sci; 2007 Dec; 13(12):856-61. PubMed ID: 17890655
[TBL] [Abstract][Full Text] [Related]
14. Proteinase-activated receptor 2: differential activation of the receptor by tethered ligand and soluble peptide analogs.
Al-Ani B; Wijesuriya SJ; Hollenberg MD
J Pharmacol Exp Ther; 2002 Sep; 302(3):1046-54. PubMed ID: 12183662
[TBL] [Abstract][Full Text] [Related]
15. Expression of protease-activated receptor-2 during embryonic development.
Jenkins AL; Chinni C; De Niese MR; Blackhart B; Mackie EJ
Dev Dyn; 2000 Jul; 218(3):465-71. PubMed ID: 10878611
[TBL] [Abstract][Full Text] [Related]
16. Intrathecal administration of proteinase-activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons.
Alier KA; Endicott JA; Stemkowski PL; Cenac N; Cellars L; Chapman K; Andrade-Gordon P; Vergnolle N; Smith PA
J Pharmacol Exp Ther; 2008 Jan; 324(1):224-33. PubMed ID: 17921188
[TBL] [Abstract][Full Text] [Related]
17. Trypsin- and SLIGRL-induced vascular relaxation and the inhibition by benzamidine derivatives.
Glusa E; Saft A; Prasa D; Stürzebecher J
Thromb Haemost; 1997 Nov; 78(5):1399-403. PubMed ID: 9408026
[TBL] [Abstract][Full Text] [Related]
18. Proteolysis of the exodomain of recombinant protease-activated receptors: prediction of receptor activation or inactivation by MALDI mass spectrometry.
Loew D; Perrault C; Morales M; Moog S; Ravanat C; Schuhler S; Arcone R; Pietropaolo C; Cazenave JP; van Dorsselaer A; Lanza F
Biochemistry; 2000 Sep; 39(35):10812-22. PubMed ID: 10978167
[TBL] [Abstract][Full Text] [Related]
19. Proteinase-activated receptors (PARs)--the PAR3 Neo-N-terminal peptide TFRGAP interacts with PAR1.
Kaufmann R; Schulze B; Krause G; Mayr LM; Settmacher U; Henklein P
Regul Pept; 2005 Feb; 125(1-3):61-6. PubMed ID: 15582715
[TBL] [Abstract][Full Text] [Related]
20. Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases.
Dulon S; Candé C; Bunnett NW; Hollenberg MD; Chignard M; Pidard D
Am J Respir Cell Mol Biol; 2003 Mar; 28(3):339-46. PubMed ID: 12594060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
